Regeneron (REGN) Reports Q4 Earnings: What Key Metrics Have to SayZacks Investment Research • 01/30/26
Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New FactoryBenzinga • 01/30/26
Regeneron Handily Beat Fourth-Quarter Forecasts — Here's Why Shares FellInvestors Business Daily • 01/30/26
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating ResultsGlobeNewsWire • 01/30/26
Regeneron Pharmaceuticals Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings CallBenzinga • 01/30/26
Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q4 Earnings?Zacks Investment Research • 01/28/26
Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 01/23/26
Nation's Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent SearchGlobeNewsWire • 01/21/26
Regeneron Pharmaceuticals, Inc. (REGN) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
Regeneron (REGN) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 01/09/26
Regeneron Pharmaceuticals upgraded by Bank of America on improving fundamentals, 2026 catalystsProactive Investors • 01/07/26
The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & JohnsonZacks Investment Research • 01/06/26
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026?Zacks Investment Research • 01/02/26
Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaGlobeNewsWire • 12/23/25
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial AsthmaGlobeNewsWire • 12/23/25
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/22/25